Potential Doribax Lawsuits are now being accepted on behalf of people who were seriously injured after taking this controversial antibacterial drug. According to the FDA, Doribax users face an increased risk of death and lower clinical cure rates compared to users of rival products. As a result of these problems, new changes have been made to Doribax drug labels discussing these risks.
Free Doribax lawsuit Evaluation: If you or a loved one has been injured by Doribax (doripenem), you should contact our law firm immediately. You may be entitled to compensation by filing a lawsuit and we can help.
What is Doribax?
Approved by the U.S. Food & Drug Administration (FDA) in October 2007, Doribax is an antibacterial medication that contains the active ingredient doripenem. Doribax is a powder designed to be diluted into a solution for intravenous (IV) drip. Doribax has received approval from the FDA for the treatment of nosocomial pneumonia (infection of the lungs that was caught in a hospital setting, including pneumonia caused by the use of a ventilator), as well as complicated infections of the abdomen and urinary tract.
FDA Warning on Doribax
On March 6, 2014, the FDA warned that Doribax had been associated with an increased risk of death and lower clinical cure rates than Primaxin (imipenem and cilastatin), another widely-prescribed antibacterial drug. Based on the analysis of a clinical trial which was stopped before it could be completed over safety concerns, FDA required that Doribax warning labels be updated with information about these risks. The new labeling includes a warning about this unapproved use. Doribax is not approved to treat any type of pneumonia.
In the clinical trial, patients diagnosed with ventilator-associated bacterial pneumonia were given either a 7-day regimen of Doribax or a 10-day treatment with Primaxin. Of these, the 28-day all-cause mortality rate was higher among Doribax users (23.0%; n=31/135) compared to those treated with Primaxin (16.7%; n=22/132). Clinical cure rates were also lower among Doribax users.
The FDA has recommended that healthcare professionals carefully consider whether the potential benefits of Doribax treatment are worth the risk to individuals with pneumonia on ventilators. View the revised Doribax Drug Label for approved label language and more information.
Do I Have a Doribax Lawsuit?
The Product Liability & Defective Drug Litigation Group at our law firm is an experienced team of trial lawyers that focus on the representation of plaintiffs in Doribax lawsuits. We are handling individual litigation nationwide and currently accepting new Doribax injury and death lawsuits in all 50 states.
Free Doribax Lawsuit Evaluation: Again, if you or a loved one has been injured by Doribax (doripenem), you should contact our law firm immediately. You may be entitled to compensation by filing a lawsuit and we can help.